Tilray Stock Surges 41% Amid Trump’s CBD Endorsement and Insider Confidence

Tilray’s Meteoric Rise: What’s Fueling the Cannabis Comeback?

On September 29, 2025, Tilray Brands (TLRY) sent shockwaves through Wall Street, surging a staggering 41% in a single day. This wasn’t just another volatile session in the unpredictable cannabis sector—it was a confluence of political headlines, insider moves, and renewed market enthusiasm.

According to Quiver Quantitative, TLRY’s trading volume exploded, crossing $202 million, as investors scrambled to react to a flurry of positive signals. The spark? President $1 Trump’s high-profile remarks on social media touting the health benefits of cannabidiol (CBD), particularly for seniors. Trump suggested CBD could revolutionize healthcare for older Americans, slow disease progression, and provide alternatives to traditional prescription drugs. His comments ignited hopes of regulatory reform, potentially reclassifying cannabis and easing criminal penalties—a shift with sweeping implications for the industry.

Political Winds Shift: Trump’s Endorsement and Regulatory Hopes

Trump’s remarks did more than just nudge investor sentiment. They fueled a rally across the sector, with cannabis stocks from Canopy Growth to Cronos Group and Aurora Cannabis all posting double-digit gains. The AdvisorShares Pure U.S. Cannabis ETF jumped more than 20% pre-market, and analysts predicted it could notch a record quarterly gain of around 70%, according to GuruFocus. Ben Laidler, equity strategist at Bradesco BBI, noted that the largest cannabis-themed ETF, MSOS, was poised for a major upswing, directly tied to Trump’s unexpected support.

But there’s more to the story than just political posturing. Trump’s hints at reclassifying cannabis could strike at the heart of the sector’s biggest pain point: Section 280E of the Internal Revenue Code. This provision currently blocks cannabis companies from taking standard business tax deductions—a costly hurdle that has kept many firms from listing on major U.S. exchanges and restricted access to capital. If reclassification becomes reality, the financial landscape for cannabis could be transformed, enabling companies like Tilray to reach a broader base of investors and scale operations.

Insider Optimism: Key Leaders Buy In

While political winds are blowing favorably, Tilray’s own leadership has been sending powerful signals of confidence. Over the past six months, insiders have made three significant open market purchases and zero sales—a pattern that stands out in a sector often plagued by uncertainty. President and CEO Irwin D. Simon acquired 165,000 shares for roughly $100,000, Chief Financial Officer Carl A. Merton bought 33,500 shares, and Global General Counsel Mitchell Gendel picked up 6,000 shares. These moves suggest that Tilray’s top brass see value where others might see risk, betting their own capital on the company’s future.

Insider buying is often interpreted as a vote of confidence, signaling that those closest to the business expect growth ahead. For Tilray, these purchases dovetail with the broader industry momentum, amplifying investor optimism and lending credibility to the bullish outlook.

Institutional Moves: Hedge Funds Adjust Positions

Institutional investors have also been reshuffling their portfolios in response to the changing landscape. Quiver Quantitative data shows 108 funds added Tilray shares in the most recent quarter, while 181 reduced their positions—a testament to the sector’s volatility and the divergent views among professional money managers.

Some of the largest moves include Citadel Advisors LLC, which dramatically increased its stake by 1,667.9%, adding over 5 million shares, and Tidal Investments LLC, which grew its holdings by 15%. On the flip side, Highbridge Capital Management LLC and Aristeia Capital, L.L.C. exited their positions entirely, removing millions of shares from their portfolios. The shifting allegiances among hedge funds reflect both the risks and the new opportunities emerging in the cannabis space.

Analyst Sentiment: Mixed, But Trending Up

Despite the euphoria, analyst price targets remain cautiously optimistic. In the last six months, two major analysts weighed in: Kaumil Gajrawala of Jefferies set a target of $2.00, while Michael Lavery of Piper Sandler pegged the stock at $1.00. The median target is $1.50—below current trading levels but above the sector’s lows earlier this year. Analysts seem to be balancing the potential upside from regulatory changes with the ongoing challenges of profitability and competition in the cannabis market.

The fact that insiders are buying while institutional investors are making large moves, and analysts are beginning to raise price targets, paints a complex but increasingly optimistic picture for Tilray’s future.

Sector Impact: Ripple Effects and Future Prospects

Tilray’s rally didn’t happen in isolation. The entire cannabis sector has been buoyed by Trump’s remarks and the possibility of reform. Companies like Canopy Growth, Cronos Group, and Aurora Cannabis all saw double-digit gains, and sector ETFs like MSOS and AdvisorShares Pure U.S. Cannabis ETF surged. The renewed interest could mark a turning point for cannabis stocks, which have struggled with regulatory headwinds and market skepticism for years.

But risks remain. Regulatory change is far from guaranteed, and past political promises have sometimes failed to materialize. The sector is still navigating complex legal terrain, with federal prohibition in the U.S. creating challenges for banking, taxation, and expansion. Investors should remain vigilant, watching for signs of real legislative movement before making long-term commitments.

Still, the convergence of insider confidence, institutional repositioning, and high-level political support has created a rare moment of optimism in cannabis investing. Tilray, as one of the sector’s most recognized brands, is at the forefront of this shift.

Tilray’s dramatic surge is a vivid illustration of how quickly sentiment can shift in response to political signals and insider activity. While the future remains uncertain, the day’s events reveal a sector hungry for change and investors ready to seize new opportunities. The coming months will test whether this optimism can be converted into lasting growth—or whether regulatory inertia will stall the cannabis renaissance once again.